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2Abstract
SHORT syndrome is a rare, recognizable syndrome resulting from heterozygous mutations in
PIK3R1 encoding a regulatory subunit of phosphoinositide-3-kinase (PI3K). The condition is
characterized by short stature, intrauterine growth restriction, lipoatrophy and a facial gestalt
involving a triangular face, deep set eyes, low hanging columella and small chin. PIK3R1
mutations in SHORT result in reduced signaling through the PI3K-AKT-mTOR pathway. We
performed whole exome sequencing for an individual with clinical features of SHORT
syndrome but negative for PIK3R1 mutation and her parents. A novel candidate variant was
identified, expressed and examined using ex vivo kinase assay. AKT-mTOR pathway
function was assessed using phospho-specific antibodies with patient lymphoblasts and
following ectopic expression of the mutant in HEK293 cells. A rare de novo variant in
PRKCE encoding PKCwas identified. Kinase analysis showed it to be partial loss-of-
function. Whilst interaction with PDK1 and the mTORC2 complex component SIN1 was
preserved in the mutant PKC, it bound to SIN1 with a higher affinity than wild-type PKC
and the dynamics of mTORC2-dependent priming of mutant PKC was altered. Further,
mutant PKC caused impaired mTORC2-dependent pAKT-S473 following rapamycin
treatment. Reduced pFOXO1-S256 and pS6-S240/244 levels were also observed in the
patient LCLs. To date, mutations in PIK3R1 causing impaired PI3K-dependent AKT
activation are the only known cause of SHORT syndrome. We identify a SHORT syndrome
child with a novel partial loss-of-function defect in PKC. This variant causes impaired AKT
activation via compromised mTORC2 complex function.
3Introduction
SHORT syndrome is a rare malformation syndrome (MIM: 269880) with less than 40
confirmed cases reported in the literature (1, 2). The acronym for SHORT syndrome is
defined as Short stature, Hyperextensibility/Inguinal Hernias, Ocular depression, Rieger
anomaly and Teething delay (1, 3). A recent appraisal of the literature of confirmed cases has
highlighted the most common features of this syndrome and this includes intrauterine growth
restriction, lipoatrophy and a facial gestalt that is near universal among those with SHORT
syndrome (1). The facial features comprise a broad forehead, deep set eyes, low-hanging
columella, prominent ears and a triangular appearance to the face and a chin that may be
dimpled (1). Other prevalent characteristics include insulin resistance, short stature and a low
body mass index (1). While there are common features, close to half (48%) of the individuals
with SHORT syndrome will have 3 or less of the features described in the acronym (1).
Mutations in PIK3R1 were identified as the cause of SHORT syndrome by ourselves and
other research groups (4-6). The mutations typically reside in the regulatory domain of
PIK3R1 that encodes the p85subunit of phosphoinositide-3-kinase (PI3K) and includes a
recurrent substitution, R649W. This p85 subunit acts to regulate the catalytic subunit (p110)
of PI3K, and when p85 is phosphorylated, it will uncouple from the p110 subunit.
Consequently, p110 is available to catalyze phosphatidylinositol (4,5) bisphosphate to
phosphatidylinositol (3,4,5) triphosphate and thereby initiate downstream phosphorylation of
targets to promote cellular growth via the PI3K-AKT-mTOR pathway. Individuals with
mutation in the p85 sequence show reduced signaling via the PI3K-AKT-mTOR network
demonstrated by diminished phosphorylation of downstream targets such as AKT, S6K and
S6 (2, 4-6).
Here we present the case of a 13 year old girl with the clinical characteristics of SHORT
syndrome and a de novo mutation in PRKCE. The mutation results in impaired activation of
AKT specifically via the mTORC2 complex-dependent branch of this pathway.
4Results
The proband was born to a 28 year old mother after a pregnancy complicated by nonimmune
fetal hydrops detected at 20 weeks gestation. A pleural shunt was inserted and the hydrops
was found to have resolved completely by 37 weeks gestation. Her mother was referred to the
genetics service, but other than a karyotype, no genetic testing was undertaken during the
pregnancy. There was no intrauterine growth restriction described during the pregnancy. She
was born by elective Caesarean section at 38 weeks and weighed 2500 grams (Z = -1.7 SD)
and with a head circumference of 33 cm (Z = -0.7 SD). She was reviewed by a geneticist in
the neonatal period who noted that she had a prominent nose, a high nasal bridge and a small
chin (Figure 1A-C). She had an unusual distribution of fat, and her abdomen had a prune
belly-like appearance. Soon after birth, she developed dusky episodes for which she was
investigated. An echocardiogram demonstrated mild mitral regurgitation and mild left
pulmonary artery branch stenosis which resolved completely by the age of 4 years.
She was reviewed regularly in the genetics clinic. Over time her scalp hair continued to be
sparse and she had hypodontia. She had pale, translucent skin with prominent vasculature and
a paucity of body fat. When reviewed at age 13 she was developmentally age appropriate and
doing well in school. There was no past history of any delays in meeting developmental
milestones (speech, fine and gross motor). She had a history of frequent bouts of otitis media
and recurrent urinary tract infections. An abdominal scan showed scarring of one kidney.
There was no history of ophthalmological concerns (no anterior chamber defects or
otherwise) or inguinal hernias. On examination at age 13 she had a height of 147.8 cm (Z = -
1.32 SD), weight of 32.54kg (Z = - 2SD) and a BMI of 15.06 (Z = -1.9). She had a triangular
face and a broad forehead (Figure 1D-E). Palpebral fissures were deep set and she had a
prominent nasal root. Her nose was long with an overhanging columella. Mouth and chin
were normally shaped with no dimple. Ears were prominent but normally positioned and with
normal structure. There were normal nails, digits and creases to hands and feet. She had
persistent primary dentition, and was lacking eight adult teeth. Extremities and her face
showed a paucity of fat and prominent vasculature. She had a pectus excavatum and a slender
body habitus.
5A diagnosis of partial lipodystrophy was initially considered, but clinical testing for
mutations in LMNA was normal and she had normal C3 nephritic factor, fasting triglycerides,
cholesterol and glucose. Later, the connective tissue abnormalities led to a consideration of
Ehlers-Danlos syndrome type IV. A skin biopsy showed irregular collagen fibrils but
COL3A1 sequencing and MLPA was negative for a mutation. A diagnosis of SHORT
syndrome was then considered on clinical grounds and the patient referred for testing of
PIK3R1.
Given the strong clinical suspicion of SHORT syndrome, targeted Sanger sequencing of
PIK3R1 was performed with no mutations identified. After WES, no obvious pathogenic
variants or small deletions/duplications in PIK3R1 or in other known genes were identified
that could explain the individual’s presentation (Supplementary Information). However, a de
novo variant in PRKCE was highlighted based on its rarity and the kinase function of its
product, Protein Kinase C family member epsilon (PKCThe Protein Kinase C family of
serine/threonine protein kinases are organized into three classes; conventional (cPKC: ),
novel (nPKC: ,,) and atypical (aPKC: ). Collectively, they influence a complex
array of diverse cellular functions including cell proliferation, survival, apoptosis and
migration (7, 8). Importantly in the context of SHORT syndrome, PKC functions in
controlling cell proliferation via the AKT-mTOR pathway (9-12). The variant identified was
NM_005400.2 (PRKCE): exon 13:c.1795G>A: p. E599K, altering a highly conserved residue
within the kinase domain of PKCFigure 2A & Supplementary Table 2. This variant was
not present in ExAC, gnomAD or ClinVar, although it was reported in a single cutaneous
melanoma sample (TCG-ER-1198) in COSMIC and cBioPortal. Multiple pathogenicity
prediction algorithms predict the variant to be damaging (Supplementary Table 1). Sanger
sequencing of the patient and her parents was performed and confirmed that the variant was
present and was de novo.
To determine the variants’ impact on the enzyme activity, E599K was introduced into a
PRKCE-containing mammalian expression vector (MYC-FLAG-pCMV6) by site-directed
mutagenesis and expressed in HEK293 cells. Following immunoprecipitation via the FLAG-
tag and elution using FLAG peptide the resultant PKC-specific eluate was tested for its
kinase activity using the PepTag PKC Kinase Activity platform (Figure 2B). The kinase
6activity of E559K was approximately 50% that of wild-type (WT) (Figure 2C). K437M is an
ATP binding defective “kinase dead” (KD) and served as a negative control. E599K retained
some activity above the kinase-dead control. Therefore, these results demonstrate E599K to
be a partial loss-of-function mutant. Furthermore, combining WT and E599K in the kinase
assay did not demonstrate additivity, suggesting a degree of dominant negativity is also a
feature of E599K (Figure 2D)
The PKC family resides in the AGC branch of the human kinome. AGC kinases, which
include AKT, share a similar mechanism of activation involving priming through
phosphorylation by other kinases of conserved priming sites within (activation loop motif,
turn motif) and C-terminal to (hydrophobic motif) their kinase domain (13, 14). For PKC
T566 represents the activation loop, T710 the turn motif, and S729 the hydrophobic motif
(Figure 2A). The kinases involved in PKC priming are PDK1 (T566) and the mTORC2
complex (T710, S729). Primed PKCcan exist in an auto-inhibited latent state through
occupation of its substrate binding pocket by its pseudosubstrate domain (Figure 3A). This
dynamic latent stage protects the phosphorylated priming sites from dephosphorylation and
facilitates rapid full activation upon subsequent substrate-mediated dynamic allosteric
conformational changes within the active site. Unprimed (unphosphorylated) PKC is
inactive. We examined priming of S729 (mTORC2-dependent) in patient LCLs using the
only commercially available phospho-specific priming antibody for PKC; that of phospho-
S729 (pPKC-S729). We found reduced levels of pPKC-S729 in PKC SHORT syndrome
LCLs compared to those of the unaffected parent (Figure 3B). We next examined the ability
of native PKCto interact with the mTORC2 priming kinase via immunoprecipitation with
the mTORC2 complex subunit SIN1 . Interestingly, we observed enhanced affinity of
PKC from the SHORT syndrome LCLs for SIN1, compared to parental LCLs (Figure 3C).
Similarly, using ectopically expressed wild-type (WT) and E599K, we observed enhanced
SIN1 affinity of the mutant PKC(Figure 3D). WT and E599K bound with grossly
comparable affinity to the other priming kinase, PDK1, under these conditions (Figure 3E).
We found that priming of S729 (mTORC2-dependent) following ectopic expression in
HEK293 cells was comparable between wild-type (WT) and E599K (Figure 3F). We
similarly found pPKC-S729 levels comparable between E599K, wild-type (WT) and a
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mutant, in these cells (Figure 3G). It is known that monitoring the dynamics of phospho-
priming on PKC family members is challenging as these are generally constitutively
phosphorylated in cell culture (16). Parker and colleagues have developed a strategy to
overcome this constitutive phosphorylation to enable the study of priming dynamics by
altering the conserved active site K residue that contacts the - phosphates of ATP (14).
This K437M kinase-dead variant is unprimed (unphosphorylated) at all priming motifs
(Figure 3G)(14). Interestingly, we found that when E599K was engineered in cis into a
K437M containing protein, this doubly mutant PKC remained primed by phosphorylation at
S729 (Figure 3H). This was in contrast to K437M alone or in cis with the constitutively
active (CA) A159E variant (Figure 3H). This suggests restricted allosteric flexibility within
the active site of PKC containing E599K. This exact phenotype is associated with markedly
reduced kinase activity in other kinase-site variants such as D532A and D532N (14).
Therefore, one possible explanation for the reduction in kinase activity we observed in
E599K (Figure 2B-D), is that the catalytic kinase domain more stably adopts a less flexible
allosteric conformation reminiscent of the latent form of PKC (Figure 3A).
AKT is also a member of the AGC kinase family and similar to PKCs requires priming
phosphorylation for optimal activity (14). In fact, phosphorylation of these priming residues
are commonly used to probe AKT activity status. The activation loop motif residue of AKT is
T308 (PDK1-dependent) and the hydrophobic motif is S473 (mTORC2-dependent).
PKChas been implicated in AKT activation via the mTORC2 complex (14). Rapamycin
(RapM) inhibits mTORC1 complex specifically, but can be used to monitor mTORC2
activity (14, 16). Using LCLs from an unaffected parent and the PKC-SHORT syndrome
individual, we monitored the phospho-status of AKT on S473 (mTORC2 phospho-site) and
T308 (PDK1 phospho-site) following treatment with RapM to leverage signaling through
mTORC2. We found reduced RapM-dependent pAKT-S473 in PKC-SHORT syndrome
LCLs, compared to the parental cells (Figure 4A). This was in contrast to phosphorylation of
the PDK1-dependent T308 site in AKT, which exhibited similar kinetics between parental
and PKC-SHORT syndrome LCLs under these conditions (Figure 4A). These findings
indicate reduced mTORC2-dependent phosphorylation and consequently full activation of
AKT in PKC-SHORT syndrome LCLs. Consequently, we also observed reduced AKT-
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compared to parental LCLs under these conditions (Figure 4A).
SHORT syndrome caused by mutant PIK3R1 (p85) has previously been shown to be
associated with reduced phospho-priming of AKT (2, 5, 6). Consistent with this we also
demonstrated incomplete AKT priming phosphorylation in p85-SHORT syndrome LCLs
following RapM treatment (Figure 4B). In this instance PDK1-dependent phospho-priming
was clearly reduced as evidenced by the lower levels of pAKT-T308 in p85-SHORT
syndrome LCLs compared to wild-type (WT) LCLs under these conditions. A positive
feedback loop between AKT and mTORC2 has recently been described and which may be
reflected in the somewhat lower RapM-induced pAKT-S473 levels seen in p85-SHORT
syndrome LCLs compared to WT here (Figure 4B) (14, 17). Reduced AKT-dependent
FOXO1 phosphorylation (pFOXO1-S256) was also observed in p85-SHORT syndrome
LCLs compared to WT under these conditions (Figure 4B).
To demonstrate impaired mTORC2-dependent AKT activation is directly caused by E599K
PKCwemodeled its impact upon AKT activation following over-expression in HEK293
cells and treatment with RapM. Reduced pAKT-S473 was observed following E599K over-
expression, similar to K437M kinase-dead (KD), and consistent with impaired AKT function
under these conditions (Figure 4C). To be optimally active AKT requires phosphorylation of
all of its priming motifs. Our findings show that E599K PKC can impair AKT priming
similarly to p85-defects, but in this instance, the impairment occurs mainly through the
established PKC-mTORC2 route.
Phorbol 12-myristated 13-acetate (PMA) can activate PKC by binding its pseudosubstrate
domain and reliving auto-inhibition. We examined AKT-mTORC1 activity following
treatment with PMA in PKC-SHORT syndrome LCLs under low serum (LS) conditions.
Whilst we did not observed a clear increase in phospho-S6 (S240, S244) following PMA in
parental LCLs, the level of pS6 was markedly reduced under these conditions specifically in
PKC SHORT syndrome LCLs (Figure 4D). These results are indicative of reduced activity
9through the AKT-mTOR-S6K-S6 pathway in PKC-SHORT syndrome, as has previously
also been described in p85-SHORT syndrome (Figure 5).
Discussion
We have presented a child with the clinical and cellular signaling deficits in keeping with
SHORT syndrome, though due to a novel, dominant, heterozygous mutation in PRKCE
versus PIK3R1. The patient’s facial features were similar to that of classical SHORT
syndrome, in particular the shape of the forehead, nose and the deep-set eyes. The lack of
family history, normal development, the history of hypodontia and her lipodystrophy were
also typical SHORT syndrome clinical features. At the cellular level, the diminished
phosphorylation of AKT and other downstream targets of the AKT-mTOR network (Figure
4) is also seen in SHORT syndrome (4, 5). Given these broad similarities we would state that
heterozygous mutation in PRKCE represent a second SHORT syndrome disease gene.
However, we would differentiate this presentation from the “Short syndrome type 2” recently
described by Pronterra et al. (18). In their report the affected child carried biallelic mutations
in IGFR1 as well as central nervous system malformations, global developmental delays,
microcephaly and elevated triglycerides, none of which would be expected in the PIK3R1- or
PRKCE-related forms of SHORT syndrome.
We recognize that the individual presented here does not have all the cardinal manifestations
described in the SHORT syndrome acronym, though this is not unexpected as only half of
individuals with SHORT syndrome, and with confirmed mutations in PIK3R1, have 4 or
more of the hallmark features (1). The individual presented here was less than average for
height, but only mildly so, and with a lower BMI but within the normal range (Z scores of
height and BMI were -1.2 and -1.9 respectively). Other SHORT syndrome features were also
absent such as anterior chamber deficits (Rieger anomaly) and inguinal hernias, but these are
present in only a minority (<30%) of those with SHORT syndrome (1). Insulin resistance is
commonly seen in SHORT syndrome but it was absent in our relatively young patient
although an oral glucose tolerance test had not been performed at the time of the manuscript
preparation. Of note, those with heterozygous, pathogenic mutations in the same pathway,
but in AKT2 (OMIM 164731), do show insulin resistance though starting in the third-fourth
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decade of life (19) and those with PIK3R1-related SHORT syndrome develop overt diabetes
in the second decade or older (20, 21).
A pathogenic role for PKC has been known for several types of cancers as it is able to
promote proliferation and inhibit apoptosis (22, 23). Constitutively active PKChas been
found in small cell lung cancer (24) and its over-expression in fibroblasts (25, 26) and
epithelial cells of the colon (27) has been associated with tumor formation with PKC being
described as an oncogene (28). Over 150 somatic mutations, mostly substitutions, in PRKCE
have been described in tumors (29). Recently, a comprehensive functional evaluation of
multiple cancer-associated PKC mutations, including those of PKC, surprisingly found none
to be activating, with most being loss-of-function (30). The PKCvariant we describe here in
SHORT syndrome (E599K) appears to be partial loss-of-function for kinase activity.
Although E599K, as noted earlier, has been described in a single instance of cutaneous
melanoma, this sample appears genomically highly complex and also contains known
oncogenic hyper-activating variants in BRAF and AKT1 (see
http://www.cbioportal.org/case.do?cancer_study_id=skcm_tcga&case_id=TCGA-ER-A198)
Nonetheless, we provide the first functional characterization of PKC E599K and show it
impairs AKT activation in the constitutional context of SHORT syndrome. Our work
highlights the synergistic benefit of combining genetic analysis with molecular-cellular
characterization of suspect pathogenic variants.
Outside of cancer, defects in PKC family members are very rare. To date, only mutations in
PRKCD encoding PKC have been identified in a human congenital disease: Systemic Lupus
Erythematosus with defective B cell apoptosis and hyper-proliferation (31). While there are
no reported loss-of-function PRKCE mutations associated with human disease, homozygous
loss-of-function mouse models of Pkcshow phenotypic similarities to our patient. Mice
homozygous for a disruption of Prkce were smaller by 10-15% and also show less overall
adipose tissue with age (32) though this has not been seen in all models (33). Nonetheless,
reduced Pkcfunctionhas also been found to impair adipogenic differentiation in mouse
preadipocyte cell culture systems (34, 35). Prkce -/- mice also show a propensity to gram
negative infections as macrophages were less sensitive to exposure to lipopolysaccharides
(32). Another knockout mouse was employed to investigate the role of PKCin insulin
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metabolism (33). These Prkce -/- mice showed an improved ability to maintain glucose levels
in fasting conditions compared to their wild-type littermates (33). Akt deficient mice are
smaller and also lack the diabetic phenotype, comparable to the Prkce -/- mice (36). Double
knockout mice deficient in Akt1 and Akt2 die shortly after birth, but show impaired
adipogenesis and significant growth restriction (37). This is in marked contrast to Pik3r1
deficient mice as they have striking evidence of insulin resistance as well as small size and
lipoatrophy (38).
In closing, we identify and characterize a novel genetic defect in SHORT syndrome. We
show that the partial loss of kinase activity of PKC E599K is associated with reduced
mTORC2-dependent phospho-priming and activation of AKT. Whilst impaired AKT
activation has previously been described as a pathomechanism underlying p85SHORT
syndrome, we show that de novo constitutional mutation in PRKCE (PKC) is similarly
associated with compromised AKT-mTOR activation, albeit mainly via impaired mTORC2
signaling (Figure 5). Our findings represent the first example of a constitutional mutation in
PRKCE (PKC) in human disease.
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Materials and Methods
The Care4Rare Canada Consortium is a collaborative research project with the goal of
identifying genetic mutations for rare childhood diseases. Institutional research ethics board
(Children’s Hospital of Eastern Ontario) approval of the study design was obtained and free
and informed consent was obtained from the study subject prior to enrollment.
Sequencing
Exome capture and high-throughput sequencing of genomic DNA was performed on the
proband and parents at the Genome Quebec Innovation Center (Montreal, Canada). Target
enrichment for the samples was performed using the Agilent SureSelect 50 Mb (V5) All
Exon Kit. Sequencing (Illumina HiSeq) generated >14 Gbp of 100 base pair, paired-end reads
per sample. Read alignment, variant calling and annotation were done as for previous
Care4Rare projects with a pipeline based on BWA(39), Picard
(http://picard.sourceforge.net/), ANNOVAR and custom annotation scripts. Reads were
aligned to hg19 with BWA 0.5.9, and indel realignment was done using the GATK(40).
Duplicate reads were then marked using Picard and excluded from downstream analyses. We
assessed coverage of consensus coding sequence (CCDS) bases using the GATK, which
showed that all samples had >95% of CCDS bases covered by at least 20 reads. Single
nucleotide variants (SNVs) and short insertions and deletions (indels) were called using
SAMtools pileup with the extended base alignment quality (BAQ) adjustment (-E), and were
then quality filtered to require at least 20% of reads supporting the variant call. Variants were
annotated using both ANNOVAR and custom scripts to identify whether they affected
protein coding sequence, in silico pathogenicity and conservation predictions, and whether
they had previously been seen in dbSNP138, the 1000 genomes dataset (2012/04 release), the
6500 NHLBI exomes (Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP),
Seattle, WA, data downloaded; 09/2015), the Exome Aggregation Consortium, or in
approximately 2000 exomes previously sequenced at the McGill University and Genome
Quebec Innovation Centre. Variants were disregarded if they were present at a frequency
higher than 5%. Sanger sequencing of the patient and her parents were also performed for the
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candidate variant(s). A summary of the variant filtering is presented as Supplementary Table
1.
Cell Lines
HEK293 cells were grown at 370C with 5% CO2 in DMEM with 10% foetal calf serum
(FCS), L-GLN and antibiotics (Pen-Strep). Patient EBV transformed lymphoblastoid cells
(LCLs) were grown in RPMI1640 supplemented with 15% FCS, L-GLN and antibiotics
(Pen-Strep).
Antibodies and chemicals
Anti-pPKCε-S729 (sc-12355) and anti--tubulin (sc-9104) were from Santa Cruz
Biotechnology. Anti-PKC(2)] was from Abcam. Mouse monoclonal anti-
FLAG® M2 (F3165) was from SIGMA-ALDRICH. Antibodies against pan-AKT (4691),
pAKT- S473 (4060), pAKT- T308 (2965), S6 (2217), pS6-S240/244 (2215), FOXO1 (2880),
pFOXO1-S256 (9461), SIN1 (12860) and PDK1 (3062) were from Cell Signaling
Technology. Rapamycin was obtained from Tocris Bioscience and Phorbol 12-myristated 13-
acetate (PMA) P8139 from SIGMA-ALDRICH.
Plasmids, site-directed mutagenesis, transfection and immunoprecipitation
PRKCE (MYC-DDK-tagged) in pCMV6 TrueORF Gold encoding human PKC
(NM_005400) was obtained from Origene (Cat# RC217702). Sequence variants were
introduced here using the QuikChange® Site-Directed Mutagenesis Kit (Cat# 200518) from
Agilent Technologies (Stratagene) according to manufacturers’ instructions. The primer pairs
are:
E599K Forward: 5' GGGTGCTGATGTACAAGATGATGGCTGGAC 3'
Reverse: 5' GTCCAGCCATCATCTTGTACATCAGCACCC 3'
K437M Forward: 5' GAAGTATATGCTGTGATGGTCTTAAAGAAGGACG 3'
Reverse: 5' CGTCCTTCTTTAAGACCATCACAGCATATACTTC 3'
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T566A Forward: 5' GTGACGACCACCGCGTTCTGTGGGAC 3'
Reverse: 5' GTCCCACAGAACGCGGTGGTCGTCAC 3'
HEK293 cells were transfected using calcium phosphate technique with 5g of plasmid
DNA, 2M CaCl2 and HBS (NaCl, Na2HPO4, HEPES pH7.5), harvested 48hrs later and the
pellet resuspended in extraction buffer (50mM Tris.HCl pH7.5, 150mM NaCl, 2mM EDTA,
2mM EGTA, 50mM NaF, 25mM β-glycerolphosphate, 0.1mM Na-orthovanadate, 0.2% 
Triton-X100, 0.3% IGEPAL, protease inhibitor cocktail (Roche)). 300g of extract was
subsequently used for immunoprecipitation with Anti-FLAG® M2 Affinity Gel (A2220 from
SIGMA-ALDRICH).
PepTag ex vivo Kinase assay
Immunoprecipitated (via FLAG-tag) PKCwas eluted from the affinity gel using 3X
FLAG® Peptide (F4799 from SIGMA-ALDRICH) and used in the non-radioactive PepTag®
assay for PKC kinase activity (V5330 from Promega), according to the manufacturers’
instructions. The PKC-specific fluorescent peptide substrate C1 peptide used is P-L-S-R-T-L-
S-V-A-A-K.
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Figure Legends
Figure 1
Photographs of the individual with PKC-SHORT syndrome. A-B show the individual as a
newborn. At birth she was noted to have a prominent nasal bridge and nose with a small chin.
C shows the individual in infancy. She had a sparseness of hair, a broad forehead, deep set
eyes, small chin, and prominent varicosities. D-E shows the individual as an adolescent. Her
face is triangular in appearance, palpebral fissures were deep set and she continued to have a
prominent nasal root. Her nose was long, narrow with an overhanging columella and small
alae nasi. Ears were prominent, and hair texture was thin.
Figure 2
A. Primary structure of PKC showing the position of the Ser/Thr kinase catalytic domain
relative to other important functional regions that constitute the regulatory domain including
C2; conventional PKC domain [Ca2+] binding region, PS; pseudosubstrate autoinhibitory
domain, C1A; actin-binding domain, C1B; PMA and diacyl glycerol (DAG)-induced
membrane binding domain. Priming phosphorylation residues include Thr566 (activation
loop motif), Thr710 (turn motif) and Ser729 (hydrophobic motif). A159E is a constitutively
active (CA) variant and K437M an ATP-binding defective kinase-dead variant. The patient
mutation E599K is indicated in grey. E599 is invariantly conserved amongst multiple
different species (Supplementary Table 2).
B. The left hand panel depicts a schematic showing how the non-radioactive fluorescent
PKC-specific peptide substrate phosphorylation is resolved by agarose gel electrophoresis
based on its net charge (“P” indicates phosphorylation). The middle panel shows a
representative agarose gel showing the kinetics of PKC-dependent phosphorylation of the
PKC reporter Phospho-PepTag peptide up to 45mins. Wild-type (WT), E599K and K437
(KD; kinase-dead) PKC expressed and immunoprecipitated from HEK293 cells was
assessed for kinase activity using this system. Recombinant PKC (recPKC) supplied with the
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assay kit served as a positive control. Reduced phospho-peptide substrate levels are observed
in E599K and K437M compared to WT and recPKC. The western blot panel below shows
equivalent expression of wild-type (WT) and E599K PKC used in the kinase activity
analysis.
C. E599K kinase activity is approximately 50% less than that of wild-type (WT). The plot
depicts a quantitation of the phospho-PepTag peptide signal at 45min time point normalised
to WT. Error bars represent the mean + S.D. (n=3) (* P <0.05 Student’s t test).
D. Equal amounts (5l each) of wild-type (WT) and E599K were mixed together an assessed
for kinase activity. Interestingly, additivity was not observed, suggesting E599K may also
exhibit a degree of dominant negativity (NS; not significant by Student’s t test).
Figure 3
A. PKC along with all AGC kinase family members require phosphorylation of specific
priming sites for optimal activity. For PKC the priming kinases include PDK1 and mTORC2
complex. Primed kinase exists in equilibrium between an autoinhibited latent kinase and a
fully active kinase. A dynamic allosteric conformational change within the catalytic kinase
domain upon substrate and ATP binding is required for full enzymatic activation.
B. Priming phosphorylation on PKC-S729 was determined using extracts derived from
parental and patient LCLs. Titration analysis indicates that pPKC-S729 were reduced in
PKC SHORT syndrome LCLs compared to parental LCLs.
C. PKC from PKC SHORT syndrome LCLs displayed enhanced affinity for the mTORC2
subunit SIN1 compared to that from parental LCLs. Endogenous SIN1 was
immunoprecipitated from LCLs and probed for PKC and SIN1, as indicated.
D. PKCE599K binds with increased affinity to SIN1 compared to wild-type (WT).
Constructs were ectopically expressed in HEK293 cells, immunoprecipitated using FLAG-
beads (IP) and western blotted with anti-SIN1. Differing exposures are shown.
E. PKCE599K binds to PDK1 with comparable affinity as wild-type (WT) PKC.
Constructs were ectopically expressed in HEK293 cells, immunoprecipitated using FLAG-
beads (IP) and western blotted with anti-PDK1. Differing exposures are shown.
F. Priming phosphorylation on PKC-S729 was determined on FLAG-immunoprecipitated
wild-type (WT) and E599K PKC following ectopic expression in HEK293 cells. Under
these conditions equal levels of pPKC-S729 were observed.
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G. Indicated constructs were ectopically expressed in HEK293 cells, immunoprecipitated
using FLAG-beads probed using anti-pPKC-S729 and anti-FLAG. Unt; untransfected, WT;
wild-type PKC, CA; constitutionally active PKC, KD; kinase-dead, and E599K; SHORT
syndrome patient variant.
H. PKCE599K exhibits altered dynamic flexibility in priming S729. As in D, E and G,
constructs were ectopically expressed in HEK293 cells, immunoprecipitated using FLAG-
beads probed using anti-pPKC-S729 and anti-FLAG. KD; this refers to K437M ATP
binding defective kinase-dead variant that strips PKCof its priming phosphorylations. KD +
CA; K473M together in cis with the constitutively active A159E. Here, priming on S729 is
also significantly reduced. KD + E599K; the patient mutation (E599K) together in cis with
the kinase-dead K473M. Here, priming on S729 is clearly detectable and demonstrates an
inflexibility in allosteric dynamics in PKC induced by E599K.
Figure 4
A. Rapamycin inhibits mTORC1 complex specifically but can be used to monitor mTORC2
complex activity. LCLs from an unaffected parent and from the PKC SHORT syndrome
individual were treated with 200nM rapamycin (RapM) as indicated and probed using
specific anti-sera for mTORC2 and PDK1-dependent priming phosphorylations on AKT.
PKC SHORT syndrome LCLs selectively exhibited attenuated mTORC2-dependent pAKT-
S473 under these conditions, compared to parental LCLs. By contrast, the kinetics of PDK1-
dependent pAKT-T308 were unaffected between patient and control LCLs. Nonetheless, for
optimal activity, AKT must be phosphorylated on both these priming residues. Consequently,
reduced pFOXO1-S256 was also observed in PKC SHORT syndrome LCLs following
RapM, compared to wild-type LCLs (WT).
B. Wild-type (WT) and p85-SHORT syndrome LCLs (PIK3R1; p.N636Tfs*18) were
treated as in B. Here, p85-SHORT syndrome LCLs exhibited markedly reduced PDK1-
dependent pAKT-T308. Reduced AKT-dependent pFOXO1-S256 was also evident under
these conditions.
C. HEK293 cells were transfected as indicated and treated with 200nM rapamycin (RapM)
and assessed for mTORC2-dependent priming phosphorylation of AKT on S473. E599K
SHORT syndrome patient mutation and the kinase-dead (KD) K473M both exhibited reduced
AKT priming under these conditions, in contrast to wild-type (WT) PKC.
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D. LCLs were grown in low serum conditions (LS; 0.5% FCS for 24hrs) before treatment
with 5M PMA as indicated. AKT-mTOR pathway activity was indirectly assessed using S6
phosphorylation on S240 and S244. Whilst PMA failed to dramatically impact upon pS6-
S240/244 levels in parental LCLs under these conditions, by contrast, PKC SHORT
syndrome LCLs clearly showed reduced pS6-S240/244 reflective of reduced AKT-mTOR
pathway activity
Figure 5
A simplified schematic demonstrating the key nodes of the PI3K-AKT-mTOR signaling
network and how these are altered in SHORT syndrome that is ultimately associated with
reduced signal transduction through this pathway. Impaired signal transduction is noted by
the dashed lines. The left-hand schematic shows the situation in SHORT syndrome caused by
dominant de novo variants in PIK3R1 which encodes the p85 regulatory subunit of PI3K.
Here, the predominant abnormality is reduced PDK1-dependent priming of AKT by
phosphorylation at T308. It is likely that PDK1-dependent priming of PKC may also be
compromised under these circumstances but we have not investigated this. The right-hand
schematic depicts the situation in SHORT syndrome caused by the dominant de novo E599K
mutation of PRKCE (PKC) identified and characterized in this study. Here we showed that
expression of this variant causes reduced mTORC2-dependent priming of AKT by
phosphorylation at S473. SIN1 is highlighted here (mTORC2 is a multicomponent complex),
because of the interaction works shown in Figurer 3. Enhanced affinity of E599K for SIN1
could disproportionally negatively impact AKT activation, by leaving a reduced pool of
SIN1-mTORC2 available to prime AKT. Importantly, AKT needs to be phosphorylated on
both these priming sites (along with its turn motif residue T450) for optimal kinase activity
and effective signaling from AKT to mTOR and further downstream. Furthermore, impacting
upon the positive feedback loop between AKT and mTORC2 via SIN1 phosphorylation by
AKT could also attenuate signaling flux. In summary, PKC SHORT syndrome, similar to
p85-SHORT syndrome, exhibits reduced AKT-mTOR activity at the level of AKT
phospho-priming. In the case of the latter this is predominantly via the PDK1 route, whilst in
the former it appears to be via the mTORC2 route.
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